Tongguan Capsule-derived Herb Reduces Susceptibility to Atrial Fibrillation by Inhibiting Left Atrial Fibrosis Via Modulating Cardiac Fibroblasts

Overview

Journal J Cell Mol Med

Specialties Cell Biology
Molecular Biology

Date 2018 Nov 21

PMID 30456908

Citations 4

Authors

Shiyu Ma

Jin Ma

Liheng Guo

Junqi Bai

Shuai Mao

Minzhou Zhang

Affiliations

Soon will be listed here.

Abstract

Tongguan capsule is a compound Chinese medicine used to treat ischaemic heart diseases. This study aimed to investigate whether Tongguan capsule-derived herb (TGD) has a preventive effect on atrial fibrillation (AF) in post-myocardial infarction (MI) rats and to determine the underlying mechanisms. MI was induced by ligation of the left anterior descending coronary artery. TGD was administered to the post-MI rats over a 4-week period. The TGD-treated rats had lower rates of AF inducibility and shorter AF durations than the MI rats. TGD improved the left atrial (LA) conduction velocity and homogeneity. It reduced the fibrosis-positive areas and the protein levels of collagen types I and III in the left atrium. In vitro, it inhibited the expression of collagen types I and III by inhibiting the proliferation, migration, differentiation and cytokine secretion of cardiac fibroblasts (CFs). In conclusion, the current study demonstrated that TGD reduces susceptibility to AF and improves LA conduction function in rats with post-MI by inhibiting left atrial fibrosis and modulating CFs. Targeting the CF population may be a novel antiarrhythmic therapeutic approach.

Citing Articles

The application and mechanism of Chinese medicine in the upstream treatment of atrial fibrillation.

Liu M, Mao C, Zhao F, Chen Z, Wang X Front Cardiovasc Med. 2023; 10:1229021.

PMID: 37608811 PMC: 10441233. DOI: 10.3389/fcvm.2023.1229021.

Left atrial fibrosis in atrial fibrillation: Mechanisms, clinical evaluation and management.

Ma J, Chen Q, Ma S J Cell Mol Med. 2021; 25(6):2764-2775.

PMID: 33576189 PMC: 7957273. DOI: 10.1111/jcmm.16350.

CYP2J2/EET reduces vulnerability to atrial fibrillation in chronic pressure overload mice.

Li X, Zhu F, Meng W, Zhang F, Hong J, Zhang G J Cell Mol Med. 2019; 24(1):862-874.

PMID: 31749335 PMC: 6933320. DOI: 10.1111/jcmm.14796.

Tongguan capsule-derived herb reduces susceptibility to atrial fibrillation by inhibiting left atrial fibrosis via modulating cardiac fibroblasts.

Ma S, Ma J, Guo L, Bai J, Mao S, Zhang M J Cell Mol Med. 2018; 23(2):1197-1210.

PMID: 30456908 PMC: 6349173. DOI: 10.1111/jcmm.14022.

References

Kume O, Takahashi N, Wakisaka O, Nagano-Torigoe Y, Teshima Y, Nakagawa M . Pioglitazone attenuates inflammatory atrial fibrosis and vulnerability to atrial fibrillation induced by pressure overload in rats. Heart Rhythm. 2010; 8(2):278-85. DOI: 10.1016/j.hrthm.2010.10.029. View

Jiang B, Li D, Deng Y, Teng F, Chen J, Xue S . Salvianolic acid A, a novel matrix metalloproteinase-9 inhibitor, prevents cardiac remodeling in spontaneously hypertensive rats. PLoS One. 2013; 8(3):e59621. PMC: 3606118. DOI: 10.1371/journal.pone.0059621. View

Zhang Y, Dedkov E, Lee 3rd B, Li Y, Pun K, Gerdes A . Thyroid hormone replacement therapy attenuates atrial remodeling and reduces atrial fibrillation inducibility in a rat myocardial infarction-heart failure model. J Card Fail. 2014; 20(12):1012-9. PMC: 4250313. DOI: 10.1016/j.cardfail.2014.10.003. View

Lajiness J, Conway S . Origin, development, and differentiation of cardiac fibroblasts. J Mol Cell Cardiol. 2013; 70:2-8. PMC: 3995835. DOI: 10.1016/j.yjmcc.2013.11.003. View

Spragg D . Left Atrial Fibrosis: Role in Atrial Fibrillation Pathophysiology and Treatment Outcomes. J Atr Fibrillation. 2017; 5(6):810. PMC: 5153181. DOI: 10.4022/jafib.810. View

Krul S, Berger W, Smit N, van Amersfoorth S, Driessen A, van Boven W . Atrial fibrosis and conduction slowing in the left atrial appendage of patients undergoing thoracoscopic surgical pulmonary vein isolation for atrial fibrillation. Circ Arrhythm Electrophysiol. 2015; 8(2):288-95. DOI: 10.1161/CIRCEP.114.001752. View

Chen B, Feng J, Su X, Meng L, Li Z, Gao Y . Effects of Tongguan Capsule on post-myocardial infarction ventricular remodeling and cardiac function in rats. Chin J Integr Med. 2010; 16(2):157-61. DOI: 10.1007/s11655-010-0157-1. View

Ma J, Ma S, Yin C, Wu H . Matrine reduces susceptibility to postinfarct atrial fibrillation in rats due to antifibrotic properties. J Cardiovasc Electrophysiol. 2018; 29(4):616-627. DOI: 10.1111/jce.13448. View

King J, Azadani P, Suksaranjit P, Bress A, Witt D, Han F . Left Atrial Fibrosis and Risk of Cerebrovascular and Cardiovascular Events in Patients With Atrial Fibrillation. J Am Coll Cardiol. 2017; 70(11):1311-1321. DOI: 10.1016/j.jacc.2017.07.758. View

10.

Qi J, Ren Y, Wang L, Guo L, Wu J, Zhang M . 6-year post-PCI follow-up of a 110-year myocardial infarction patient: a case report. Int J Cardiol. 2014; 176(3):e119-21. DOI: 10.1016/j.ijcard.2014.07.234. View

11.

Qi J, Yu J, Wang L, Guo L, Ma S, Huang D . Tongguan Capsule Protects against Myocardial Ischemia and Reperfusion Injury in Mice. Evid Based Complement Alternat Med. 2013; 2013:159237. PMC: 3774060. DOI: 10.1155/2013/159237. View

12.

Lee K, Everett 4th T, Rahmutula D, Guerra J, Wilson E, Ding C . Pirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failure. Circulation. 2006; 114(16):1703-12. PMC: 2129103. DOI: 10.1161/CIRCULATIONAHA.106.624320. View

13.

Rahman F, Kwan G, Benjamin E . Global epidemiology of atrial fibrillation. Nat Rev Cardiol. 2016; 13(8):501. DOI: 10.1038/nrcardio.2016.114. View

14.

Gong P, Li Y, Yao C, Guo H, Hwang H, Liu X . Traditional Chinese Medicine on the Treatment of Coronary Heart Disease in Recent 20 Years. J Altern Complement Med. 2017; 23(9):659-666. DOI: 10.1089/acm.2016.0420. View

15.

Rahman F, Kwan G, Benjamin E . Global epidemiology of atrial fibrillation. Nat Rev Cardiol. 2014; 11(11):639-54. DOI: 10.1038/nrcardio.2014.118. View

16.

Heijman J, Voigt N, Nattel S, Dobrev D . Cellular and molecular electrophysiology of atrial fibrillation initiation, maintenance, and progression. Circ Res. 2014; 114(9):1483-99. DOI: 10.1161/CIRCRESAHA.114.302226. View

17.

Milliez P, Deangelis N, Rucker-Martin C, Leenhardt A, Vicaut E, Robidel E . Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction. Eur Heart J. 2005; 26(20):2193-9. DOI: 10.1093/eurheartj/ehi478. View

18.

Woods C, Olgin J . Atrial fibrillation therapy now and in the future: drugs, biologicals, and ablation. Circ Res. 2014; 114(9):1532-46. PMC: 4169264. DOI: 10.1161/CIRCRESAHA.114.302362. View

19.

Kakkar R, Lee R . Intramyocardial fibroblast myocyte communication. Circ Res. 2010; 106(1):47-57. PMC: 2805465. DOI: 10.1161/CIRCRESAHA.109.207456. View

20.

Atienza F, Martins R, Jalife J . Translational research in atrial fibrillation: a quest for mechanistically based diagnosis and therapy. Circ Arrhythm Electrophysiol. 2012; 5(6):1207-15. PMC: 3535065. DOI: 10.1161/CIRCEP.111.970335. View